science
Trump Administration Sets $245 Monthly Price for GLP-1 Drugs in Medicare and Medicaid with $50 Copay Requirement
The November agreement with Eli Lilly and Novo Nordisk covered obesity indications previously excluded from Medicare. Coverage required private Medicare insurers to offer the drugs at a $50 copay.
globalnews.caAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The Trump administration reached an agreement in November that set a monthly price of $245 for GLP-1 drugs in Medicare and Medicaid. The price was intended to apply to all GLP-1 drugs, including those indicated for obesity. Medicare had not covered GLP-1 drugs for obesity treatment before the agreement.
The $245 price was contingent on private Medicare insurers agreeing to cover the drugs for all uses with a $50 copay. The administration did not publicly disclose the private-insurer coverage condition at the time of the agreement.
The agreement was reached between the Trump administration and Eli Lilly and Novo Nordisk. The article reporting these details was published on June 30, 2026.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
